Cargando…

Low-Intensity Pulsed Ultrasound-Mediated Blood-Brain Barrier Opening Increases Anti-Programmed Death-Ligand 1 Delivery and Efficacy in Gl261 Mouse Model

Therapeutic antibodies targeting immune checkpoints have shown limited efficacy in clinical trials in glioblastoma (GBM) patients. Ultrasound-mediated blood–brain barrier opening (UMBO) using low-intensity pulsed ultrasound improved drug delivery to the brain. We explored the safety and the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahmed, Mohammed H., Hernández-Verdin, Isaias, Quissac, Emie, Lemaire, Nolwenn, Guerin, Coralie, Guyonnet, Lea, Zahr, Noël, Mouton, Laura, Santin, Mathieu, Petiet, Alexandra, Schmitt, Charlotte, Bouchoux, Guillaume, Canney, Michael, Sanson, Marc, Verreault, Maïté, Carpentier, Alexandre, Idbaih, Ahmed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967384/ https://www.ncbi.nlm.nih.gov/pubmed/36839777 http://dx.doi.org/10.3390/pharmaceutics15020455

Ejemplares similares

Heterogeneity of Response to Iron-Based Metallodrugs in Glioblastoma Is Associated with Differences in Chemical Structures and Driven by FAS Expression Dynamics and Transcriptomic Subtypes
por: Vessières, Anne, et al.
Publicado: (2021)

Anthracycline-induced cytotoxicity in the GL261 glioma model system
por: Tavener, Amber M., et al.
Publicado: (2021)

A therapeutic cancer vaccine against GL261 murine glioma
por: Kindy, Mark S., et al.
Publicado: (2016)

Perfluorocarbon emulsions radiosensitise brain tumors in carbogen breathing mice with orthotopic GL261 gliomas
por: Feldman, Lisa A., et al.
Publicado: (2017)

Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model
por: McKelvey, Kelly J., et al.
Publicado: (2020)

Unveiling the enigma of the blood–brain barrier in glioblastoma: current advances from preclinical and clinical studies
por: Ahmed, Mohammed H., et al.
Publicado: (2023)

Convective forces increase CXCR4-dependent glioblastoma cell invasion in GL261 murine model
por: Cornelison, R. Chase, et al.
Publicado: (2018)

Anti-PD-1 checkpoint blockade monotherapy in the orthotopic GL261 glioma model: the devil is in the detail
por: Tritz, Zachariah P, et al.
Publicado: (2021)

Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells
por: Clark, Aaron J, et al.
Publicado: (2014)

GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models
por: Sanchez, Victoria E., et al.
Publicado: (2020)

Unraveling response to temozolomide in preclinical GL261 glioblastoma with MRI/MRSI using radiomics and signal source extraction
por: Núñez, Luis Miguel, et al.
Publicado: (2020)

Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice
por: Ferrer-Font, Laura, et al.
Publicado: (2017)

Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas
por: Enríquez Pérez, Julio, et al.
Publicado: (2020)

Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8(+) T-cell responses and immune memory
por: Wu, Junjie, et al.
Publicado: (2015)

A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model
por: Towner, Rheal A., et al.
Publicado: (2015)

Live-cell calcium imaging of adherent and non-adherent GL261 cells reveals phenotype-dependent differences in drug responses
por: Strong, Averey D., et al.
Publicado: (2017)

Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells
por: Villamañan, Lucía, et al.
Publicado: (2021)

Author Correction: GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models
por: Sanchez, Victoria E., et al.
Publicado: (2022)

Irradiation-Modulated Murine Brain Microenvironment Enhances GL261-Tumor Growth and Inhibits Anti-PD-L1 Immunotherapy
por: Garbow, Joel R., et al.
Publicado: (2021)

Longitudinal [(18)F]GE-180 PET Imaging Facilitates In Vivo Monitoring of TSPO Expression in the GL261 Glioblastoma Mouse Model
por: Holzgreve, Adrien, et al.
Publicado: (2022)

Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses
por: Renner, Danielle N., et al.
Publicado: (2015)

Pyk2/FAK Signaling Is Upregulated in Recurrent Glioblastoma Tumors in a C57BL/6/GL261 Glioma Implantation Model
por: Ortiz Rivera, Jescelica, et al.
Publicado: (2023)

Microglia and astrocytes attenuate the replication of the oncolytic vaccinia virus LIVP 1.1.1 in murine GL261 gliomas by acting as vaccinia virus traps
por: Kober, Christina, et al.
Publicado: (2015)

Intratumoral INF-γ triggers an antiviral state in GL261 tumor cells: a major hurdle to overcome for oncolytic vaccinia virus therapy of cancer
por: Kober, Christina, et al.
Publicado: (2015)

Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches
por: Wu, Shuang, et al.
Publicado: (2020)

Phenotypic selection through cell death: stochastic modelling of O-6-methylguanine-DNA methyltransferase dynamics
por: Lasri, Ayoub, et al.
Publicado: (2020)

A New Pharmacokinetic Model Describing the Biodistribution of Intravenously and Intratumorally Administered Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in a GL261 Xenograft Glioblastoma Model
por: Klapproth, Alexander P, et al.
Publicado: (2020)

Immune System-Related Changes in Preclinical GL261 Glioblastoma under TMZ Treatment: Explaining MRSI-Based Nosological Imaging Findings with RT-PCR Analyses
por: Calero-Pérez, Pilar, et al.
Publicado: (2021)

The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model
por: Ortiz-Rivera, Jescelica, et al.
Publicado: (2023)

A New Pharmacokinetic Model Describing the Biodistribution of Intravenously and Intratumorally Administered Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in a GL261 Xenograft Glioblastoma Model [Corrigendum]
Publicado: (2020)

Identification of growth hormone receptor as a relevant target for precision medicine in low‐EGFR expressing glioblastoma
por: Verreault, Maïté, et al.
Publicado: (2022)

Temporary disruption of the blood-brain barrier using an implantable ultrasound system for recurrent glioblastoma patients under IV carboplatin chemotherapy: initial phase 1/2a clinical trial observations
por: Carpentier, Alexandre, et al.
Publicado: (2015)

Health Tract, No. 261: Boils
Publicado: (1866)

Evaluation of TgH(CX3CR1-EGFP) mice implanted with mCherry-GL261 cells as an in vivo model for morphometrical analysis of glioma-microglia interaction
por: Resende, Fernando F. B., et al.
Publicado: (2016)

Biocompatible coated magnetosome minerals with various organization and cellular interaction properties induce cytotoxicity towards RG-2 and GL-261 glioma cells in the presence of an alternating magnetic field
por: Hamdous, Yasmina, et al.
Publicado: (2017)

IMMU-05. B7-H3-SPECIFIC CAR T CELLS HAVE POTENT ANTI-TUMOR ACTIVITY IN THE GL261 IMMUNE-COMPETENT MURINE BRAIN TUMOR MODEL
por: Haydar, Dalia, et al.
Publicado: (2020)

Pan-cancer landscape of AID-related mutations, composite mutations, and their potential role in the ICI response
por: Hernández-Verdin, Isaias, et al.
Publicado: (2022)

PMM no. 26.1 & 4.2
Publicado: (1981)

OpenGL
por: Wright, Richard S., 1965-
Publicado: (2005)

261. Adaptive Immunosuppression in Children with Septic Shock
por: Cruz Vidal, Diego A, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cjqf4so2rcbqv7p8pml7ncq4lh